Bosnia and Herzegovina vs Congo: Protecting minority investors: Ease of shareholder suits index (0-10)
Bosnia and Herzegovina
50
in 2019
Congo
50
in 2019
Bosnia and Herzegovina rank
128th
Congo rank
128th
Protecting minority investors: Ease of shareholder suits index (0-10) over time
- Bosnia and Herzegovina
- Congo
How they compare
Bosnia and Herzegovina currently reports 50 against 50 in Congo, a difference of 0.
The two have swapped places 1 time across 7 shared years of data; in 2013 it was Bosnia and Herzegovina ahead.
Bosnia and Herzegovina ranks 128th and Congo ranks 128th of 191 countries.
Bosnia and Herzegovina has averaged higher in every one of the 1 decades both report.
Frequently asked questions
- Which has higher protecting minority investors: ease of shareholder suits index (0-10), Bosnia and Herzegovina or Congo?
- Bosnia and Herzegovina, at 50 against 50 in Congo as of 2019.
- What is the difference in protecting minority investors: ease of shareholder suits index (0-10) between Bosnia and Herzegovina and Congo?
- 0, with Bosnia and Herzegovina ahead.
- How many years of comparable data are there for Bosnia and Herzegovina and Congo?
- 7 years are reported by both, from 2013 to 2019.
- How do Bosnia and Herzegovina and Congo rank globally for protecting minority investors: ease of shareholder suits index (0-10)?
- Bosnia and Herzegovina ranks 128th and Congo ranks 128th of 191 countries.
- Where does this data come from?
- The World Bank, published as Protecting minority investors: Ease of shareholder suits index (0-10) (DB15-20 methodology) - Score. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The score for ease of shareholder suits index benchmarks economies with respect to the regulatory best practice on the indicator. The score is indicated on a scale from 0 to 100, where 0 represents the worst regulatory performance and 100 the best regulatory performance, and is computed based on the methodology in the DB15-20 studies.